Rice bioengineers shed light on dosing challenges for cancer immunotherapy
A team of Rice bioengineers has developed a mathematical model that clarifies why interleukin-12 ⎯ a potent immune-boosting protein that holds promise for cancer treatment ⎯ loses effectiveness over time when used as an immunotherapeutic.
